Associate Professor Nikki Verrills
Associate Professor
School of Biomedical Sciences and Pharmacy (Medical Biochemistry)
- Email:nikki.verrills@newcastle.edu.au
- Phone:(02) 4921 5619
Honing in on her target
Dr Nikki Verrills' research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.
As a young undergraduate studying science, Dr Nikki Verrills had intentions of transferring to medicine. Then, she discovered a passion for laboratory research and realised she could effectively fight disease on another front.
"In the end I have achieved the best of both worlds," the biochemist and cancer researcher points out. "I am still in the medical field helping patients by contributing to the development of better treatments but I am also able to pursue my interest in lab work, which I find fascinating."
Verrills has certainly found her niche. Since completing her PhD in 2005 she has worked largely full-time in academic research, collecting a clutch of early career awards, fellowships and major grants in recognition of her groundbreaking research into leukaemia and breast cancer. She studies the molecular pathways of cancer, identifying genes and proteins in cancer cells in order to make comparisons between normal cells and cancer cells. She also analyses differences between cancer cells that respond well to drug treatments and those that do not.
"If scientists can identify proteins that are different in cancerous cells, or in drug-resistant cells, then we can design drugs to target those differences – drugs that will specifically kill cancerous cells but not normal cells," she explains. "That is fundamental cancer research, but most cancer drugs work by turning off a particular protein, or inactivating it. What is novel about our work is that we have targeted a protein that needs to be switched back on."
That protein is phosphatase 2A, or PP2A, which comes from a class of proteins known as 'tumour suppressors'. Normally, they act as a stop signal to inhibit the growth of cancerous cells. In leukaemia cells, however, PP2A is inactive, so the cancer cells continue to proliferate.
In 2007, Verrills worked with collaborators in the United States to prove that the drug FTY720 could effectively switch PP2A on in patients with chronic myeloid leukaemia (CML) – therefore stopping the cancer's spread without affecting the body's healthy cells. This year she was awarded a $360,000 grant from the Cure Cancer Australia Foundation and Cancer Council NSW to apply that research to a different cancer, acute myeloid leukaemia (AML), which has a very poor survival rate.
"There is a real urgency to find new treatments for AML because the vast majority of patients are resistant to chemotherapy and will die of the disease," Verrills asserts. The grant will allow Verrills and her team to test FTY720 and other drugs in different sub-types of AML, and move their work from the laboratory into clinical trials.
"Another focus of our work is establishing exactly how these types of drugs work," she outlines. "We know the end result is that they increase activity of PP2A but we want to advance the knowledge in this field by finding out specifically how they do that. Also, we know from literature that this class of proteins is important in a lot of solid tumours, so it is likely that this research will be applicable to other cancers as well."
Verrills has received ongoing support from high-profile national cancer organisations and has forged collaborations with key research groups in Australia and internationally. She also works closely with colleagues in the University's Centres for Cancer and Chemical Biology and through her links with the Hunter Medical Research Institute (HMRI) has established important working relationships with cancer specialists and haematologists. Her articles are published in internationally prominent journals and she has been recognised with a Voiceless Eureka Prize for Research for her commitment to minimising the use of animals in laboratory work.
Verrills' doctoral studies into chemotherapy resistance in childhood leukaemia led to a Peter Doherty Postdoctoral Fellowship from the National Health and Medical Research Council in 2006. In the same year she was the inaugural recipient of a Hunter Medical Research Foundation grant for young cancer researchers. She is currently supported by an Early Career Researcher Fellowship with the Cancer Institute of NSW.
Verrills gained exposure during her doctoral studies to cutting-edge scientific techniques used at the Australian Proteomic Analysis Facility, in Sydney, becoming one of the first researchers in the country to use Difference In-Gel Electrophoresis (DIGE). This technique allows simultaneous analysis of proteins in cancerous, non-cancerous and control cells and vastly improves the efficiency and accuracy of testing.
The scientist admits that work/life balance is an elusive concept given her demanding research career, two young daughters and family interest in a vineyard (in which her husband Michael De Iuliis, a fellow scientist, is chief winemaker). But she praises the support of the University of Newcastle, which has allowed her to maintain the momentum of her research while juggling life's other commitments.
"Not only has the University supported me but it has also shown a lot of confidence in me, which is critical for career advancement," Verrills acknowledges. "I have my own research group and I have reached the stage of being an independent researcher much earlier than I probably would have anywhere else."
Visit the Priority Research Centre for Cancer
Visit the Priority Research Centre for Drug Development
Visit the HMRI website
Honing in on her target
Dr Nikki Verrills’ research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.
Career Summary
Biography
Dr Verrills research interests centre on understanding the signalling pathways involved in cancer development, progression and resistance to chemotherapy induced cell death. Her research involves cell biology and biochemistry, translation into clinically relevant mouse models of disease, and analysis of primary patient samples. During her PhD studies Dr Verrills used powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, to discover novel protein alterations that confer chemotherapy resistance in childhood leukaemia.
In postdoctoral studies Dr Verrills further applied her proteomics skills to the investigation of respiratory disease, and has identified clinical biomarkers for asthma and chronic obstructive pulmonary disease. These proteins are now targets for patent applications and ongoing investigations into the development of diagnostics and improved therapies. Her postdoctoral studies in respiratory disease led to an interest in signalling pathways, with particular interest in the multifunctional protein phosphatase, PP2A. This led her to establish a research group investigating the role of protein phosphatase 2A (PP2A) in cellular functions. Her group has discovered novel roles for PP2A in cellular function and disease, including myeloid leukaemias, melanoma and asthma, and demonstrated that PP2A activation is a potential strategy for improved therapies (e.g. senior author papers in Cancer Research and Cell Signalling, and co-authored papers in Nature Medicine, Journal of Clinical Investigation; J Biol Chem; BBA; Cell Death & Diff). She has developed a unique panel of PP2A molecular reagents (shRNA, overexpression constructs, antibodies, pharmacological activators/inhibitors), and established strategic collaborations which has enabled her to expand her investigations of PP2A into the study of breast cancer.
Her PhD was awarded from Macquarie University in 2005, for which she received a Vice-Chancellor’s Commendation for Excellence in Research. In 2006 Dr Verrills received a highly competitive NHMRC Peter Doherty Postdoctoral Fellowship. Through this fellowship she also received a scholarship to the Australian Academy of Science “Science at the Shine Dome” meeting. In 2006 she also became the inaugural recipient of the Hunter Medical Research Institute (HMRI) Competitive Research Fund for Early Career Researchers in Cancer. In 2010 Dr Verrills was appointed to an ongoing academic position (Lecturer) at the University of Newcastle, however in 2011 she was awarded a Cancer Institute NSW Early Career Research Development Award, and after deferring this for a year for maternity leave, she took up this fellowship in Dec 2011. After 6 years part-time, she returned to full time in late 2017 with the award of an ARC Future Fellowship, and a CINSW Career Development Fellowship (which had to be declined due to the ARC Fellowship). Dr Verrills was promoted to Associate Professor in 2019, and was awarded an ongoing teaching and research academic position at the conclusion of the ARC Fellowship in 2021.
See the Publication, Grants and Funding and Supervision tabs above for up to date information and statistics for these areas.
The Projects tab contains information about the current Verrills Laboratory projects and members.
Dr Verrills has a strong commitment to the advancement and promotion of medical research in our society. As part of her community involvement she has disseminated her research through the print, radio, and television media, and has presented her research to the local community as a guest speaker at Rotary and Lions Clubs, and HMRI, Cure Cancer Australia, and Cancer Council NSW charity events. Through the Tall Poppy Campaign she has also presented her research to High School students across NSW, and has established relationships with her local school communities to foster and encourage an interest in studying science.
Qualifications
- PhD, Macquarie University
- Bachelor of Science (Honours), Macquarie University
Keywords
- Breast Cancer
- Cancer
- Chemotherapy resistance
- Drug resistance
- Leukaemia
- Protein phosphatase 2A
- Proteomics
- Signal transduction
Fields of Research
Code | Description | Percentage |
---|---|---|
320506 | Medical biochemistry - proteins and peptides (incl. medical proteomics) | 60 |
321101 | Cancer cell biology | 40 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Associate Professor | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
21/5/2015 - 21/6/2015 | Postdoctoral Scientist | University of Newcastle Australia |
1/1/2012 - 31/12/2013 | Membership - NHMRC Grant Review Panel | NHMRC Grant Review Panel Australia |
1/1/2011 - | Fellow | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
1/1/2011 - | Cancer Institute NSW ECD Research Fellow | Family Action Centre University of Newcastle Australia |
1/1/2006 - 1/7/2010 |
Peter Doherty Biomedical Fellow NHMRC - Early Career Fellowships (Formerly Postdoctoral Training Fellowships) |
National Health & Medical Research Council |
1/1/2001 - | Membership - Australian Society for Medical Research | Australian Society for Medical Research (ASMR) Australia |
1/1/1999 - 2/1/2001 | Research Assistant | Macquarie University Australia |
Membership
Dates | Title | Organisation / Department |
---|---|---|
Organising Committee Member - HMRI Conference on Translational Cancer Research | Hunter Medical Research Institute (HMRI) Australia |
|
Committee Member - HMRI Cancer Research Group Steering Committee | Hunter Medical Research Institute (HMRI) Australia |
|
Member - American Association of Cancer Research | American Association of Cancer Research United States |
|
1/1/2021 - |
Committee Member Member of the Steering Committee |
the Analytical and Biomolecular Research Facility (ABRF) Advisory Group of University of Newcastle Australia |
Awards
Honours
Year | Award |
---|---|
1998 |
Bill Cantwell prize for Excellence in Biology Macquarie University |
Nomination
Year | Award |
---|---|
2017 |
Cancer Institute NSW Research Fellow of the Year Finalist Cancer Institute NSW |
2016 |
Cancer Institute NSW Research Fellow of the Year Finalist Cancer Institute NSW |
Recipient
Year | Award |
---|---|
2017 |
Cancer Institute NSW Career Development Fellowship (declined due to ARC) Cancer Institute NSW |
2017 |
ARC Future Fellowship ARC (Australian Research Council) |
2012 |
Newcastle Innovations Rising Star Award Newcastle Innovation |
2011 |
Cancer Institute NSW Early Career Fellowship Cancer Institute NSW |
2006 |
NHMRC Peter Doherty Postdoctoral Fellowship NHMRC (National Health & Medical Research Council) |
2003 |
Australian Proteome Analysis Facility Scholarship 2001-2003 Australian Proteome Analysis Facility |
2003 |
Australian Postgraduate Award 2001-2003 Macquarie University |
Recognition
Year | Award |
---|---|
2019 |
Supervisor of the Year Award, School of Biomedical Sciences and Pharmacy University of Newcastle |
2005 |
2005 - Doctor of Philosophy, Vice Chancellor Commendation. Macquarie University |
2003 |
2003 - Cure Cancer Australia Foundation's Young Researcher of the Year Award - Finalist. Cure Cancer Australia Foundation |
Research Award
Year | Award |
---|---|
2007 |
Young Tall Poppy Award AIPS (Australian Institute of Policy and Science) |
2007 |
HuPO Young Guns Award Human Proteome Organization |
2007 |
University of Newcastle Vice Chancellor’s Award for Research Excellence University of Newcastle |
2007 |
Voiceless Eureka Prize Australian Museum |
2006 |
Science at the Shine Dome Award Australian Academy of Sciences |
2004 |
Biochemical Journal Young Investigator Award - 12th International Conference on Second Messengers and Phosphoproteins The Biochemical Journal |
2004 |
2004 - Merck Sharp Dohm 'Best of the Best' Award - Australian Health and Medical Research Congress Australian Society of Medical Research |
2004 |
2004 - Cure Cancer Australia Foundation Award Cure Cancer Australia Foundation |
2003 |
2003 - University of Sydney Medal for Excellence in Medical Research Australian Society of Medical Research |
Invitations
Participant
Year | Title / Rationale |
---|---|
2003 |
Protemics for cancer research Organisation: Oncology Research Unit, Childrens Hospital, Westmead. |
2003 |
Proteome analyses reveals novel mechanisms of resistance to anticancer agents. Organisation: Oncology Research Unit, Childrens Hospital, Westmead. |
2003 |
Amersham Biosciences Technical Seminar Series. Brisbane; Adelaide; Melbourne; Sydney. Organisation: GE Biosciences Description: Amersham Biosciences, now part of GE Healthcare, is a world leader in proteomics technology. I was invited as an expert presenter on the use of state of the art proteomic technology, 2D difference gel electrophoresis, and how this technology can be applied in biomedical research. |
2002 |
New technologies meets functional proteomics. Organisation: ComBio 2002 Description: This was a special session at the ComBio meeting convened bythe Australian Proteomics Society and was an invited speaker. |
Teaching
Code | Course | Role | Duration |
---|---|---|---|
HUBS3302 |
Bioinformatics and Functional Genomics The University of Newcastle - School of Biomedical Sciences and Pharmacy |
Guest Lecturer | 1/1/2010 - 31/12/2025 |
HUBS2209 |
Human Cell Biology and Cancer The University of Newcastle - School of Biomedical Sciences and Pharmacy |
Guest Lecturer | 1/1/2010 - 31/12/2025 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (1 outputs)
Year | Citation | Altmetrics | Link |
---|---|---|---|
2011 | Smith AM, Roberts KG, Verrills NM, 'Ser/Thr phosphatases: The new frontier for myeloid leukemia therapy?', Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Intech, Croatia 123-148 (2011) [B1] | Nova |
Journal article (74 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2023 |
Germon ZP, Sillar JR, Mannan A, Duchatel RJ, Staudt D, Murray HC, et al., 'Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.', Sci Signal, 16 eabp9586 (2023) [C1]
|
Nova | |||||||||
2023 |
Murray HC, Miller K, Brzozowski JS, Kahl RGS, Smith ND, Humphrey SJ, et al., 'Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.', Mol Cell Proteomics, 22 100503 (2023) [C1]
|
Nova | |||||||||
2022 |
Tiburcius S, Krishnan K, Patel V, Netherton J, Sathish C, Weidenhofer J, et al., 'Triple Surfactant Assisted Synthesis of Novel Core-Shell Mesoporous Silica Nanoparticles with High Surface Area for Drug Delivery for Prostate Cancer', BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, 95 331-340 (2022) [C1]
|
Nova | |||||||||
2022 |
Radhakrishnan D, Mohanan S, Choi G, Choy J-H, Tiburcius S, Trinh HT, et al., 'The emergence of nanoporous materials in lung cancer therapy', SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS, 23 225-274 (2022) [C1]
|
Nova | |||||||||
2022 |
Hunt K, Burnard SM, Roper EA, Bond DR, Dun MD, Verrills NM, et al., 'scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs', SCIENTIFIC REPORTS, 12 (2022) [C1]
|
Nova | |||||||||
2022 |
Martin JH, Mohammed R, Delforce SJ, Skerrett-Byrne DA, de Meaultsart CC, Almazi JG, et al., 'Role of the prorenin receptor in endometrial cancer cell growth', Oncotarget, 13 587-599 (2022) [C1]
|
Nova | |||||||||
2022 |
Tiburcius S, Krishnan K, Jose L, Patel V, Ghosh A, Sathish C, et al., 'Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells', NANOSCALE, 14 6830-6845 (2022) [C1]
|
Nova | |||||||||
2022 |
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, et al., 'Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection', CLINICAL PROTEOMICS, 19 (2022) [C1]
|
Nova | |||||||||
2021 |
Trinh HT, Mohanan S, Radhakrishnan D, Tiburcius S, Yang JH, Verrills NM, et al., 'Silica-based nanomaterials as drug delivery tools for skin cancer (melanoma) treatment', Emergent Materials, 4 1067-1092 (2021) [C1] Skin cancer has emerged as one of the leading types of cancers in the world, causing a high impact on the global burden of health and the economy. Basal cell and squamous cell car... [more] Skin cancer has emerged as one of the leading types of cancers in the world, causing a high impact on the global burden of health and the economy. Basal cell and squamous cell carcinoma are the localized forms of skin cancer with a high prevalence and can be treated with a high success rate. However, melanoma, a rare type of skin cancer with a high mortality rate, can metastasize and invade other parts of the body. Various skin cancer treatment approaches have been developed and advanced from localized to systemic treatment over the years to improve the low success rate associated with skin cancer, especially metastatic melanoma. The systemic treatment of skin cancer is highly benefitted by drug delivery systems (DDS) designed to function with much higher specificity and lower side effects than the direct treatment with drugs. While many nanomaterials based DDS have been developed in the past few years to take advantage of the small size and high functionality of nanomaterials, silica-based nanomaterials have recently emerged as the flexible DDS with a high biocompatibility, good clearance, a high drug loading capacity, and versatility to attach several drugs and targeting agents to its surface. In this review, recent progress in the treatment of melanoma using silica-based nanomaterials and their hybrids is discussed, highlighting the versatility and potential of these emerging nanomaterials as the DDS for delivering various molecules, including drugs and immunotherapy agents, peptides, and radio- and photo-active agents. The review also introduces various therapies available for the treatment of melanoma, including surgery, chemotherapy, targeted therapy, phototherapy, and immunotherapy and discusses the improvement in these therapies based on silica-based DDS. The review also highlights the role of silica nanomaterials and their hybrids in delivering combination therapy and the advantages of silica nanohybrids over pure silica-based DDS. Finally, we summarize the present status of silica-based nanomaterials in melanoma treatment and the current challenges that have to be solved for the clinical translation of these materials as DDS.
|
Nova | |||||||||
2021 |
Tiburcius S, Krishnan K, Yang JH, Hashemi F, Singh G, Radhakrishnan D, et al., 'Silica-Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment', Chemical Record, 21 1535-1568 (2021) [C1] Prostate cancer (PCa) is one of the most commonly diagnosed cancers and is the fifth common cause of cancer-related mortality in men. Current methods for PCa treatment are insuffi... [more] Prostate cancer (PCa) is one of the most commonly diagnosed cancers and is the fifth common cause of cancer-related mortality in men. Current methods for PCa treatment are insufficient owing to the challenges related to the non-specificity, instability and side effects caused by the drugs and therapy agents. These drawbacks can be mitigated by the design of a suitable drug delivery system that can ensure targeted delivery and minimise side effects. Silica based nanoparticles (SBNPs) have emerged as one of the most versatile materials for drug delivery due to their tunable porosities, high surface area and tremendous capacity to load various sizes and chemistry of drugs. This review gives a brief overview of the diagnosis and current treatment strategies for PCa outlining their existing challenges. It critically analyzes the design, development and application of pure, modified and hybrid SBNPs based drug delivery systems in the treatment of PCa, their advantages and limitations.
|
Nova | |||||||||
2020 |
Dun MD, Mannan A, Rigby CJ, Butler S, Toop HD, Beck D, et al., 'Shwachman Bodian Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia', Leukemia, 34 3393-3397 (2020) [C1]
|
Nova | |||||||||
2020 |
Panicker N, Coutman M, Lawlor-O'Neill C, Kahl RGS, Roselli S, Verrills NM, 'Ppp2r2aKnockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55 alpha, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development', FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 8 (2020) [C1]
|
Nova | |||||||||
2019 |
Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, et al., 'Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".', Science translational medicine, 11 1-4 (2019) [C1]
|
Nova | |||||||||
2019 |
Nader CP, Cidem A, Verrills NM, Ammit AJ, 'Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer', RESPIRATORY RESEARCH, 20 (2019) [C1]
|
Nova | |||||||||
2019 |
Nair PM, Starkey MR, Haw TJ, Liu G, Collison AM, Mattes J, et al., 'Enhancing tristetraprolin activity reduces the severity of cigarette smoke-induced experimental chronic obstructive pulmonary disease', CLINICAL & TRANSLATIONAL IMMUNOLOGY, 8 (2019) [C1]
|
Nova | |||||||||
2018 |
Almazi JG, Pockney P, Gedye C, Smith ND, Hondermarck H, Verrills NM, Dun MD, 'Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.', Proteomics. Clinical applications, 12 e1700121 (2018) [C1]
|
Nova | |||||||||
2018 |
Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, Dun MD, 'Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19 (2018) [C1]
|
Nova | |||||||||
2018 |
Degryse S, De Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, et al., 'Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia', Leukemia, 32 788-800 (2018) [C1] Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellu... [more] Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellular transformation and the development of T-ALL in mouse models. However, the signal transduction pathways downstream of JAK3 mutations remain poorly characterized. Here we describe the phosphoproteome downstream of the JAK3(L857Q)/(M511I) activating mutations in transformed Ba/F3 lymphocyte cells. Signaling pathways regulated by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib. Comprehensive network interrogation using the phosphoproteomic signatures identified significant changes in pathways regulating cell cycle, translation initiation, mitogen-activated protein kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling, RNA metabolism, as well as epigenetic and apoptotic processes. Key regulatory proteins within pathways that showed altered phosphorylation following JAK inhibition were targeted using selumetinib and trametinib (MEK), buparlisib (PI3K) and ABT-199 (BCL2), and found to be synergistic in combination with JAK kinase inhibitors in primary T-ALL samples harboring JAK3 mutations. These data provide the first detailed molecular characterization of the downstream signaling pathways regulated by JAK3 mutations and provide further understanding into the oncogenic processes regulated by constitutive kinase activation aiding in the development of improved combinatorial treatment regimens.
|
Nova | |||||||||
2017 |
Ong LK, Page S, Briggs GD, Guan L, Dun MD, Verrills NM, et al., 'Peripheral Lipopolysaccharide Challenge Induces Long-Term Changes in Tyrosine Hydroxylase Regulation in the Adrenal Medulla', Journal of Cellular Biochemistry, 118 2096-2107 (2017) [C1] Immune activation can alter the activity of adrenal chromaffin cells. The effect of immune activation by lipopolysaccharide (LPS) on the regulation of tyrosine hydroxylase (TH) in... [more] Immune activation can alter the activity of adrenal chromaffin cells. The effect of immune activation by lipopolysaccharide (LPS) on the regulation of tyrosine hydroxylase (TH) in the adrenal medulla in vivo was determined between 1 day and 6 months after LPS injection. The plasma levels of eleven cytokines were reduced 1 day after LPS injection, whereas the level for interleukin-10 was increased. The levels of all cytokines remained at control levels until 6 months when the levels of interleukin-6 and -4 were increased. One day after LPS injection, there was a decrease in TH-specific activity that may be due to decreased phosphorylation of serine 31 and 40. This decreased phosphorylation of serine 31 and 40 may be due to an increased activation of the protein phosphatase PP2A. One week after LPS injection, there was increased TH protein and increased phosphorylation of serine 40 that this was not accompanied by an increase in TH-specific activity. All TH parameters measured returned to basal levels between 1 month and 3 months. Six months after injection there was an increase in TH protein. This was associated with increased levels of the extracellular regulated kinase isoforms 1 and 2. This work shows that a single inflammatory event has the capacity to generate both short-term and long-term changes in TH regulation in the adrenal medulla of the adult animal. J. Cell. Biochem. 118: 2096¿2107, 2017. © 2016 Wiley Periodicals, Inc.
|
Nova | |||||||||
2017 |
Murray HC, Dun MD, Verrills NM, 'Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer', Expert Opinion on Drug Discovery, 12 431-447 (2017) [C1] Introduction: Genomic and transcriptomic profiling of tumours has revolutionised our understanding of cancer. However, the majority of tumours possess multiple mutations, and dete... [more] Introduction: Genomic and transcriptomic profiling of tumours has revolutionised our understanding of cancer. However, the majority of tumours possess multiple mutations, and determining which oncogene, or even which pathway, to target is difficult. Proteomics is emerging as a powerful approach to identify the functionally important pathways driving these cancers, and how they can be targeted therapeutically. Areas covered: The authors provide a technical overview of mass spectrometry based approaches for proteomic profiling, and review the current and emerging strategies available for the identification of dysregulated networks, pathways, and drug targets in cancer cells, with a key focus on the ability to profile cancer kinomes. The potential applications of mass spectrometry in the clinic are also highlighted. Expert opinion: The addition of proteomic information to genomic platforms¿¿proteogenomics¿¿is providing unparalleled insight in cancer cell biology. Application of improved mass spectrometry technology and methodology, in particular the ability to analyse post-translational modifications (the PTMome), is providing a more complete picture of the dysregulated networks in cancer, and uncovering novel therapeutic targets. While the application of proteomics to discovery research will continue to rise, improved workflow standardisation and reproducibility is required before mass spectrometry can enter routine clinical use.
|
Nova | |||||||||
2017 |
Nair PM, Starkey MR, Haw TJ, Liu G, Horvat JC, Morris JC, et al., 'Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice', Allergy: European Journal of Allergy and Clinical Immunology, 72 1891-1903 (2017) [C1] Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to allergens. Protein phosphatase-2A (PP2A) is an abundant serine/threonine phosphatase ... [more] Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to allergens. Protein phosphatase-2A (PP2A) is an abundant serine/threonine phosphatase with anti-inflammatory activity. The ubiquitin proteasome system (UPS) controls many cellular processes, including the initiation of inflammatory responses by protein degradation. We assessed whether enhancing PP2A activity with fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-2-methylbutan-1-ol (AAL (S) ), or inhibiting proteasome activity with bortezomib (BORT), could suppress experimental AAD. Methods: Acute AAD was induced in C57BL/6 mice by intraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OVA. Chronic AAD was induced in mice with prolonged i.n exposure to crude house dust mite (HDM) extract. Mice were treated with vehicle, FTY720, AAL (S) , BORT or AAL (S) +BORT and hallmark features of AAD assessed. Results: AAL (S) reduced the severity of acute AAD by suppressing tissue eosinophils and inflammation, mucus-secreting cell (MSC) numbers, type 2-associated cytokines (interleukin (IL)-33, thymic stromal lymphopoietin, IL-5 and IL-13), serum immunoglobulin (Ig)E and airway hyper-responsiveness (AHR). FTY720 only suppressed tissue inflammation and IgE. BORT reduced bronchoalveolar lavage fluid (BALF) and tissue eosinophils and inflammation, IL-5, IL-13 and AHR. Combined treatment with AAL (S) +BORT had complementary effects and suppressed BALF and tissue eosinophils and inflammation, MSC numbers, reduced the production of type 2 cytokines and AHR. AAL (S) , BORT and AAL (S) +BORT also reduced airway remodelling in chronic AAD. Conclusion: These findings highlight the potential of combination therapies that enhance PP2A and inhibit proteasome activity as novel therapeutic strategies for asthma.
|
Nova | |||||||||
2017 |
Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al., 'Functional importance of PP2A regulatory subunit loss in breast cancer', Breast Cancer Research and Treatment, 166 117-131 (2017) [C1] Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathways involved in proliferation, survival and apo... [more] Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathways involved in proliferation, survival and apoptosis. PP2A inhibition occurs in many cancers and is considered a tumour suppressor. Deletion/downregulation of PP2A genes has been observed in breast tumours, but the functional role of PP2A subunit loss in breast cancer has not been investigated. Methods: PP2A subunit expression was examined by immunohistochemistry in human breast tumours, and by qPCR and immunoblotting in breast cancer cell lines. PP2A subunits were inhibited by shRNA, and mutant PP2A genes overexpressed, in MCF10A and MCF7 cells, and growth and signalling in standard and three-dimensional cultures were assessed. Results: Expression of PP2A-Aa, PP2A-Ba and PP2A-B'a subunits was significantly lower in primary human breast tumours and lymph node metastases, compared to normal mammary tissue. PP2A-Aa and the regulatory subunits PP2A-Ba, -Bd and -B'¿ were also reduced in breast cancer cell lines compared to normal mammary epithelial cells. Functionally, shRNA-mediated knockdown of PP2A-Ba, -B'a and -B'¿, but not PP2A-Aa, induced hyper-proliferation and large multilobular acini in MCF10A 3D cultures, characterised by activation of ERK. Expression of a breast cancer-associated PP2A-A mutant, PP2A-Aa-E64G, which inhibits binding of regulatory subunits to the PP2A core, induced a similar hyper-proliferative phenotype. Knockdown of PP2A-Ba also induced hyper-proliferation in MCF7 breast cancer cells. Conclusion: These results suggest that loss of specific PP2A regulatory subunits is functionally important in breast tumourigenesis, and support strategies to enhance PP2A activity as a therapeutic approach in breast cancer.
|
Nova | |||||||||
2017 |
Ross EA, Naylor AJ, O'Neil JD, Crowley T, Ridley ML, Crowe J, et al., 'Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression', Annals of the Rheumatic Diseases, 76 612-619 (2017) [C1] Objectives Tristetraprolin (TTP), a negative regulator of many pro-inflammatory genes, is strongly expressed in rheumatoid synovial cells. The mitogen-activated protein kinase (MA... [more] Objectives Tristetraprolin (TTP), a negative regulator of many pro-inflammatory genes, is strongly expressed in rheumatoid synovial cells. The mitogen-activated protein kinase (MAPK) p38 pathway mediates the inactivation of TTP via phosphorylation of two serine residues. We wished to test the hypothesis that these phosphorylations contribute to the development of inflammatory arthritis, and that, conversely, joint inflammation may be inhibited by promoting the dephosphorylation and activation of TTP. Methods The expression of TTP and its relationship with MAPK p38 activity were examined in non-inflamed and rheumatoid arthritis (RA) synovial tissue. Experimental arthritis was induced in a genetically modified mouse strain, in which endogenous TTP cannot be phosphorylated and inactivated. In vitro and in vivo experiments were performed to test anti-inflammatory effects of compounds that activate the protein phosphatase 2A (PP2A) and promote dephosphorylation of TTP. Results TTP expression was significantly higher in RA than non-inflamed synovium, detected in macrophages, vascular endothelial cells and some fibroblasts and co-localised with MAPK p38 activation. Substitution of TTP phosphorylation sites conferred dramatic protection against inflammatory arthritis in mice. Two distinct PP2A agonists also reduced inflammation and prevented bone erosion. In vitro anti-inflammatory effects of PP2A agonism were mediated by TTP activation. Conclusions The phosphorylation state of TTP is a critical determinant of inflammatory responses, and a tractable target for novel anti-inflammatory treatments.
|
Nova | |||||||||
2017 |
Delforce SJ, Lumbers ER, de Meaultsart CC, Wang Y, Proietto A, Otton G, et al., 'Expression of renin-angiotensin system (RAS) components in endometrial cancer', ENDOCRINE CONNECTIONS, 6 9-19 (2017) [C1]
|
Nova | |||||||||
2016 |
Patel BS, Rahman MM, Rumzhum NN, Oliver BG, Verrills NM, Ammit AJ, 'Theophylline Represses IL-8 Secretion from Airway Smooth Muscle Cells Independently of Phosphodiesterase Inhibition. Novel Role as a Protein Phosphatase 2A Activator.', Am J Respir Cell Mol Biol, 54 792-801 (2016) [C1]
|
Nova | |||||||||
2016 |
Enjeti AK, D'Crus A, Melville K, Verrills NM, Rowlings P, 'A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia', Anti-Cancer Drugs, 27 560-568 (2016) [C1] Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator tha... [more] Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indications. The initial positive results of PP2A activators in vitro and mouse models of AML are promising; however, its safety for use in AML has not been assessed. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML. A literature review was carried out to assess safety before the commencement of Phase I trials of the PP2A activator Fingolimod in AML. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML. A systematic review of published literature in Medline, EMBASE and the Cochrane Library of critical reviews was carried out. International standards for the design and reporting of search strategies were followed. Search terms and medical subject headings used in trials involving PP2A activators as well as a specific search were performed for 'adverse events','serious adverse events', 'delays in treatment', ' side effects' and 'toxicity' for primary objectives. Database searches were limited to papers published in the last 12 years and available in English. The search yielded 677 articles. A total of 69 journal articles were identified as relevant and included 30 clinical trials, 24 review articles and 15 case reports. The most frequently reported adverse events were nausea, diarrhoea, fatigue, back pain, influenza viral infections, nasopharyngitis and bronchitis. Specific safety concerns include monitoring of the heart rate and conduction at commencement of treatment as cardiotoxicity has been reported. There is little evidence to suggest specific bone marrow toxicity. Lymophopenia is a desired effect in the management of multiple sclerosis, but may have implications in patients with acute leukaemia as it may potentially increase susceptibility to viral infections such as influenza. Fingolimod is a potential treatment option for AML with an acceptable risk to benefit ratio, given its lack of bone marrow toxicity and the relatively low rate of serious side effects. As most patients with AML are elderly, specific monitoring for cardiac toxicity as well as infection would be required.
|
Nova | |||||||||
2016 |
Rahman MM, Rumzhum NN, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ, 'Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells', Cellular Signalling, 28 325-334 (2016) [C1] Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thus, novel... [more] Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thus, novel anti-inflammatory strategies are necessary. The mRNA destabilizing protein, tristetraprolin (TTP), is an anti-inflammatory molecule that functions to induce mRNA decay of cytokines that drive pathogenesis of respiratory disorders. TTP is regulated by phosphorylation and protein phosphatase 2A (PP2A) is responsible for dephosphorylating (and hence activating) TTP, amongst other targets. PP2A is activated by small molecules, FTY720 and AAL(S), and in this study we examine whether these compounds repress cytokine production in a cellular model of airway inflammation using A549 lung epithelial cells stimulated with tumor necrosis factor a (TNFa) in vitro. PP2A activators significantly increase TNFa-induced PP2A activity and inhibit mRNA expression and protein secretion of interleukin 8 (IL-8) and IL-6; two key pro-inflammatory cytokines implicated in respiratory disease and TTP targets. The effect of PP2A activators is not via an increase in TNFa-induced TTP mRNA expression; instead we demonstrate a link between PP2A activation and TTP anti-inflammatory function by showing that specific knockdown of TTP with siRNA reversed the repression of TNFa-induced IL-8 and IL-6 mRNA expression and protein secretion by FTY720. Therefore we propose that PP2A activators affect the dynamic equilibrium regulating TTP; shifting the equilibrium from phosphorylated (inactive) towards unphosphorylated (active) but unstable TTP. PP2A activators boost the anti-inflammatory function of TTP and have implications for future pharmacotherapeutic strategies to combat inflammation in respiratory disease.
|
Nova | |||||||||
2016 |
Rahman MM, Prunte L, Lebender LF, Patel BS, Gelissen I, Hansbro PM, et al., 'The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells', SCIENTIFIC REPORTS, 6 (2016) [C1]
|
Nova | |||||||||
2016 |
Rahman MM, Prabhala P, Rumzhum NN, Patel BS, Wickop T, Hansbro PM, et al., 'TLR2 ligation induces corticosteroid insensitivity in A549 lung epithelial cells: Anti-inflammatory impact of PP2A activators', International Journal of Biochemistry and Cell Biology, 78 279-287 (2016) [C1] Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic respiratory diseases. But these medicines can lose their efficacy during respiratory infection... [more] Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic respiratory diseases. But these medicines can lose their efficacy during respiratory infection resulting in disease exacerbation. Further in vitro research is required to understand how infection worsens lung function control in order to advance therapeutic options to treat infectious exacerbation in the future. In this study, we utilize a cellular model of bacterial exacerbation where we pretreat A549 lung epithelial cells with the synthetic bacterial lipoprotein Pam3CSK4 (a TLR2 ligand) to mimic bacterial infection and tumor necrosis factor a (TNFa) to simulate inflammation. Under these conditions, Pam3CSK4 induces corticosteroid insensitivity; demonstrated by substantially reduced ability of the corticosteroid dexamethasone to repress TNFa-induced interleukin 6 secretion. We then explored the molecular mechanism responsible and found that corticosteroid insensitivity induced by bacterial mimics was not due to altered translocation of the glucocorticoid receptor into the nucleus, nor an impact on the NF-¿B pathway. Moreover, Pam3CSK4 did not affect corticosteroid-induced upregulation of anti-inflammatory MAPK deactivating phosphatase¿MKP-1. However, Pam3CSK4 can induce oxidative stress and we show that a proportion of the MKP-1 produced in response to corticosteroid in the context of TLR2 ligation was rendered inactive by oxidation. Thus to combat inflammation in the context of bacterial exacerbation we sought to discover effective strategies that bypassed this road-block. We show for the first time that known (FTY720) and novel (theophylline) activators of the phosphatase PP2A can serve as non-steroidal anti-inflammatory alternatives and/or corticosteroid-sparing approaches in respiratory inflammation where corticosteroid insensitivity exists.
|
Nova | |||||||||
2016 |
Toop HD, Dun MD, Ross BK, Flanagan HM, Verrills NM, Morris JC, 'Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia', Organic and Biomolecular Chemistry, 14 4605-4616 (2016) [C1] AAL(S), the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines. It has been suggested that it ... [more] AAL(S), the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines. It has been suggested that it does this by activating protein phosphatase 2A (PP2A). Here we report the synthesis of new cytotoxic analogs of AAL(S) and the evaluation of their cytotoxicity in two myeloid cell lines, one of which is sensitive to PP2A activation. We show that these analogs activate PP2A in these cells supporting the suggested mechanism for their cytotoxic properties. Our findings identify key structural motifs required for anti-cancer effects.
|
Nova | |||||||||
2016 |
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7 47465-47478 (2016) [C1] Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leuke... [more] Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+ BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+ cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.
|
Nova | |||||||||
2015 |
Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, et al., 'PR55a-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity', Oncogene, 34 1333-1339 (2015) [C1] The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexes that regulates processes essential for embryonic development, tissue homeostas... [more] The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexes that regulates processes essential for embryonic development, tissue homeostasis and malignant transformation. Induction of gene expression by c-Jun involves stimulation of its transactivation ability and upregulation of DNA binding capacity. While it is well established that the former requires JNK-mediated phosphorylation of S63/S73, the mechanism(s) through which binding of c-Jun to its endogenous target genes is regulated remains poorly characterized. Here we show that interaction of c-Jun with chromatin is positively regulated by protein phosphatase 2A (PP2A) complexes targeted to c-Jun by the PR55a regulatory subunit. PR55a-PP2A specifically dephosphorylates T239 of c-Jun, promoting its binding to genes regulating tumour cell migration and invasion. PR55a-PP2A also enhanced transcription of these genes, without affecting phosphorylation of c-Jun on S63. These findings suggest a critical role for interplay between JNK and PP2A pathways determining the functional activity of c-Jun/AP-1 in tumour cells.
|
Nova | |||||||||
2015 |
Tay KH, Liu X, Chi M, Jin L, Jiang CC, Guo ST, et al., 'Involvement of vacuolar H Targeting the sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signalling axis is emerging as a promising strategy in the treatment of cancer. However, the effect of such an appr... [more] Targeting the sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signalling axis is emerging as a promising strategy in the treatment of cancer. However, the effect of such an approach on survival of human melanoma cells remains less understood. Here, we show that the sphingosine analogue FTY720 that functionally antagonises S1PRs kills human melanoma cells through a mechanism involving the vacuolar H+-ATPase activity. Moreover, we demonstrate that FTY720-triggered cell death is characterized by features of necrosis and is not dependent on receptor-interacting protein kinase 1 or lysosome cathepsins, nor was it associated with the activation of protein phosphatase 2A. Instead, it is mediated by increased production of reactive oxygen species and is antagonized by activation of autophagy. Collectively, these results suggest that FTY720 and its analogues are promising candidates for further development as new therapeutic agents in the treatment of melanoma.
|
Nova | |||||||||
2015 |
Rahman MM, Rumzhum NN, Morris JC, Clark AR, Verrills NM, Ammit AJ, 'Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin', SCIENTIFIC REPORTS, 5 (2015) [C1]
|
Nova | |||||||||
2014 |
Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ, 'Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.', Nucleic Acids Research, 42 9195-9208 (2014) [C1]
|
Nova | |||||||||
2014 |
Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014) [C1] Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning... [more] Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in¿vitro. Objective: We sought to elucidate the molecular mechanisms by which ß-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor ¿B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in¿vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits. © 2013 American Academy of Allergy, Asthma & Immunology.
|
Nova | |||||||||
2014 |
Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1] Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation... [more] Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation. The biological properties of CaMKII are regulated by multi-site phosphorylation and targeting via interactions with specific proteins. To investigate the role specific CaMKII phosphorylation sites play in controlling cell proliferation and cell cycle progression, we examined phosphorylation of CaMKII at two sites (T253 and T286) at various stages of the cell cycle, and also examined the effects of overexpression of wild-type (WT), T286D phosphomimic, T253D phosphomimic and T253V phosphonull forms of CaMKIIa in MDA-MB-231 breast cancer and SHSY5Y neuroblastoma cells on cellular proliferation and cell cycle progression. We demonstrate herein that whilst there is no change in total CaMKII expression or T286 phosphorylation throughout the cell cycle, a marked dephosphorylation of CaMKII at T253 occurs during the G2 and/or M phases. Additionally, we show by molecular inhibition, as well as pharmacological activation, that protein phosphatase 2A (PP2A) is the phosphatase responsible for this dephosphorylation. Furthermore, we show that inducible overexpression of WT, T286D and T253V forms of CaMKIIa in MDA-MB-231 and SHSY5Y cells increases cellular proliferation, with no alteration in cell cycle profiles. By contrast, overexpression of a T253D phosphomimic form of CaMKIIa significantly decreases proliferation, and cells accumulate in mitosis, specifically in metaphase. Taken together, these results strongly suggest that the dephosphorylation of CaMKII at T253 is involved in controlling the cell cycle, specifically the metaphase-anaphase transition. © 2014 Elsevier Inc.
|
Nova | |||||||||
2013 |
Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
|
Nova | |||||||||
2012 |
Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
|
||||||||||
2012 |
Bradbury P, Mahmassani M, Zhong J, Turner K, Paul A, Verrills NM, O'Neill GM, 'PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9', Biochimica Et Biophysica Acta-Molecular Cell Research, 1823 290-297 (2012) [C1]
|
Nova | |||||||||
2012 |
Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 (2012) [C1]
|
Nova | |||||||||
2011 |
Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
|
Nova | |||||||||
2011 |
Roberts KG, McDougall FK, Verrills NM, 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Response', Cancer Research, 71 2404-2404 (2011) [C3]
|
||||||||||
2011 |
Chang H-Y, Jennings PC, Stewart JL, Verrills NM, Jones KT, 'Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720', Journal of Biological Chemistry, 286 14705-14712 (2011) [C1]
|
Nova | |||||||||
2011 |
Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al., 'Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 183 1633-1643 (2011) [C1]
|
Nova | |||||||||
2010 |
Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
|
Nova | |||||||||
2010 |
Kranias G, Watt L, Carpenter HC, Holst J, Ludowyke R, Strack S, et al., 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', Cellular Signalling, 22 1882-1890 (2010) [C1]
|
Nova | |||||||||
2010 |
Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
|
Nova | |||||||||
2009 |
Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, 110, Suppl. 2 42 (2009) [E3]
|
||||||||||
2009 |
Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, 110, Suppl. 2 40-41 (2009) [E3]
|
||||||||||
2008 |
Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, 106 51 (2008) [E3]
|
||||||||||
2007 |
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al., 'FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia', Journal of Clinical Investigation, 117 2408-2421 (2007) [C1]
|
||||||||||
2006 |
Verrills NM, Po'Uha ST, Liu MLM, Liaw TYE, Larsen MR, Ivery MT, et al., 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98 1363-1374 (2006) [C1]
|
Nova | |||||||||
2006 | Verrills NM, 'Clinical proteomics: present and future prospects', Clinical Biochemist Reviews, 27 99-116 (2006) [C2] | ||||||||||
2006 |
Sim AT, Ludowyke RI, Verrills NM, 'Mast cell function: Regulation of degranulation by serine/threonine phosphatases', Pharmacology & Therapeutics, 112 425-439 (2006) [C1]
|
Nova | |||||||||
2006 |
Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M, 'Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6 1681-1694 (2006) [C1]
|
Nova | |||||||||
Show 71 more journal articles |
Conference (53 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2020 |
Staudt D, Kahl R, Skerrett-Byrne D, Murray H, Jamaluddin M, Woldu AS, et al., 'Proteomic and phosphoproteomic profiling of wildtype (-WT and -FL) and mutant FLT3 (-ITD,-D835V/Y, -and ITD/D835V/Y) signaling pathways in acute myeloid leukemia', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
|
|||||||
2020 |
Germon ZP, Sillar JR, Mannan A, Duchatel R, Murray HC, Douglas A, et al., 'Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
|
|||||||
2019 |
Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Dun MD, Verrills NM, 'Phosphoproteomic Characterisation of Acute Myeloid Leukaemia (AML)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
|
|||||||
2015 |
Pearsall E, Chi M, Yoon E-J, Gilchrist J, Verrills N, Skelding KA, 'BAALC can control the sensitivity of AML cells to chemotherapeutics', The 2015 Hunter Cancer Research Symposium Program, Newcastle (2015) [E3]
|
|||||||
2015 |
Ross EA, Smallie T, Naylor AJ, Desanti GE, Crowe J, O'Neil JD, et al., 'TRISTETRAPROLIN IS A NOVEL THERAPEUTIC TARGET FOR RHEUMATOID ARTHRITIS', ANNALS OF THE RHEUMATIC DISEASES (2015)
|
|||||||
2015 |
Watt LF, Panicker N, Copeland B, Kahl RGS, Dun MD, Young B, et al., 'PP2A a novel biomarker and therapeutic target for poor outcome breast cancer', Proceedings of the Lowy Cancer Conference, Sydney (2015) [E3]
|
|||||||
2015 |
Dun M, Murray H, Al-mazi J, Kahl R, Flanagan H, Smith N, et al., 'IDENTIFICATION AND SYNERGISTIC TARGETING OF FLT3-ACTIVATED PATHWAYS IN ACUTE MYELOID LEUKAEMIA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Al-mazi J, Dun M, Smith N, Verrills N, 'DEVELOPMENT OF NOVEL MULTIPLE REACTION MONITORING (MRM) ASSAY FOR BIOMARKER QUANTITATION IN CANCER CELLS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Lehman W, Kahl R, Flanagan H, Verrills N, Dun M, 'DETERMINING THE MECHANISM OF LEUKAEMOGENESIS INDUCED BY SHWACHMAN-DIAMOND SYNDROME (SDS) USING COMPARATIVE AND QUANTITATIVE PROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Li X, Flanagan H, Kahl R, Rigby C, Verrills N, Dun M, 'CHEMICAL PROTEOMICS TO IDENTIFY THE MECHANISM OF PROTEIN PHOSPHATASE 2A (PP2A) INHIBITION IN ACUTE MYELOID LEUKAEMIA (AML)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Mannan A, Panicker N, Watt L, Kahl R, Dun M, Skelding K, Verrills N, 'ROLE OF REDUCED PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, EXPRESSION IN LUMINAL B BREAST CANCER CELL LINE DNA DAMAGE REPAIR PATHWAY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Panicker N, Watt L, Kahl R, Dun M, Greer P, Skelding K, Verrills N, 'REDUCED EXPRESSION OF PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, IN BREAST CANCER DNA DAMAGE REPAIR PATHWAYS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Rigby C, Kahl R, Flanagan H, Li X, Enjeti A, Verrills N, Dun M, 'CHARACTERISATION OF A NOVEL PP2A INHIBITORY ONCOPROTEIN IN ACUTE MYELOID LEUKAEMIA (AML)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Udeh R, Kahl R, Flanagan H, Verrills N, Dun M, 'IDENTIFYING THE FUNCTIONAL ROLE OF TSR, A NOVEL DRUG TARGET IN AML', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 | Rahman M, Rumzhum NN, Clark AR, Verrills NM, Ammit AJ, 'Basal Protein Phosphatase 2a Activity Restrains Cytokine Expression In A549 Lung Epithelial Cells: Role For Mapks And Tristetraprolin', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Denver, CO (2015) | |||||||
2014 |
Delforce SJ, Pringle KG, Wang Y, Verrills NM, Scott RJ, Lumbers ER, 'THE FUNCTIONAL ROLE OF THE ENDOMETRIAL RENIN ANGIOTENSIN SYSTEM IN ENDOMETRIAL CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Yoon E-J, Chi MN, Enjeti AK, Verrills NM, Skelding KA, 'CHARACTERISING A NEW TARGET FOR THE TREATMENT OF ACUTE LEUKAEMIAS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Dun MD, Kahl RGS, Flanagan H, Cairns MMJ, Smith ND, Enjeti AK, et al., 'IDENTIFICATION OF ONCOGENIC SIGNALLING PATHWAYS IN ACUTE MYELOID LEUKAEMIA (AML) PATIENTS BY PHOSPHOPROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
De Iuliis GN, Verrills NM, Dun MD, 'IN SILICO ANALYSIS OF THE TARGETS OF SMALL-MOLECULE, ANTI-CANCER COMPOUNDS FOR IMPROVED CANCER THERAPEUTICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2013 |
Dun MD, Smith AM, Kahl RGS, Smith ND, Khanna A, Don AS, et al., 'Unraveling the mechanism of action: drugs that activate the tumor suppressor 2A.', CANCER RESEARCH, Washington, DC (2013) [E3]
|
|||||||
2012 |
Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
|
|||||||
2011 |
Collison AM, Hatchwell LM, Pereira De Siqueira AL, Don A, Verrills NM, Foster PS, Mattes J, 'The development of house dust mite-induced allergic airways disease is regulated by a novel E3 ubiquitin ligase-dependent deactivation of a protein phosphatase', Respirology, Perth, WA (2011) [E3]
|
|||||||
2011 |
Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology, Perth, WA (2011) [E3]
|
|||||||
2010 |
Irwin J, Verrills NM, He XY, Powell H, Wood LG, Gibson PG, 'Proteomic biomarkers as novel clinical diagnostics for airway disease', Abstract Book. Human Proteome World Congress Sydney 2010, Sydney, NSW (2010) [E3]
|
|||||||
2010 |
Verrills NM, Roberts KG, Smith AM, McDougall FK, Carpenter HC, Neviani P, et al., 'Targeting the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
|
|||||||
2010 | Gilan O, Jastrezebski K, Diesch J, Verrills NM, Hannan RD, Dhillon AS, 'Functional regulation of the Fra-1/AP-1 Transcription factor via interactions with protein phosphatase 2A', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3] | |||||||
2010 |
Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
|
|||||||
2010 |
Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
|
|||||||
2009 | Kranias G, Cottrell LF, Carpenter HC, Sim AT, Verrills NM, 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', FEBS Journal, Prague, Czech Republic (2009) [E3] | |||||||
2009 |
Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
|
|||||||
2009 |
Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
|
|||||||
2008 |
Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
|
|||||||
2007 |
Roberts KG, Ashman LK, Sim AT, Verrills NM, 'Regulation of protein phosphatase 2A (PP2A) B subunits by Bcr/Abl: Potential targets for chronic myeloid leukemia', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
|
|||||||
2006 |
Chang MHY, Engelander J, Verrills NM, Tait AS, Kavallaris M, 'Differential proteomic analysis of low-level anti-microtubule resistance in acute lymphoblastic leukaemia (Poster presentation)', 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (European Journal of Cancer Supplements, Vol 4, no. 12), Prague, Czech Republic (2006) [E3]
|
|||||||
2006 | Verrills NM, Carpenter HC, Sim AT, 'Disruption of Actin-containing Protein Phosphatase 2A Complexes Regulates Cell Motility in Neuroblastoma Cells', Molecular & Cellular Proteomics, California, USA (2006) [E3] | |||||||
Show 50 more conferences |
Preprint (3 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2024 |
Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Reinhardt LS, et al., 'Upregulated cholesterol biosynthesis facilitates the survival of methylation-retaining AML cells following decitabine treatment (2024)
|
|||||||
2022 |
Germon Z, Sillar J, Mannan A, Duchatel R, Staudt D, Murray H, et al., 'Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies (2022)
|
|||||||
2021 |
Hunt K, Burnard S, Roper E, Bond D, Dun M, Verrills N, et al., 'SINEultaneous profiling of epigenetic heterogeneity and transcriptome in single cells (2021)
|
Grants and Funding
Summary
Number of grants | 87 |
---|---|
Total funding | $15,551,673 |
Click on a grant title below to expand the full details for that specific grant.
20233 grants / $204,995
Targeting cholesterol biosynthesis for improved efficacy of hypomethylating agents in acute myeloid leukaemia$100,000
Funding body: Cure Cancer Australia Foundation
Funding body | Cure Cancer Australia Foundation |
---|---|
Project Team | Doctor Danielle Bond, Professor Matt Dun, Doctor Anoop Enjeti, Doctor Heather Lee, Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2200647 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
Targeting insulin signalling to overcome resistance to venetoclax in acute myeloid leukaemia (AML)$100,000
Funding body: Cure Cancer Australia Foundation
Funding body | Cure Cancer Australia Foundation |
---|---|
Project Team | Doctor Heather Murray, Dr Natasha Anstee, Doctor Natasha Anstee, Professor Matt Dun, Doctor Anoop Enjeti, Associate Professor Nikki Verrills, Prof Andrew Wei |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2200755 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
Elucidating markers of response to hypomethylating agents in blood cancers$4,995
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Doctor Heather Murray, Doctor Jonathan Sillar, Dr Ashwin Unnikrishnan, Associate Professor Nikki Verrills |
Scheme | Pilot Funding Scheme |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300457 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20222 grants / $1,634,937
Cardiovascular disease and cancer: identifying shared disease pathways and pharmacological management$1,029,267
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo, Professor Murray Cairns, Doctor Heather Lee, Associate Professor Nikki Verrills, Doctor Craig Gedye, Doctor Tatt Jhong Haw, Professor John Attia, Professor Michael Kelso, Dr Daniel Tillett, Dr James Lynam, Dr James Lynam, Associate Professor Anoop Enjeti, Dr Susan Dent, Kerry Doyle, OAM, Susan Dent, Kerry Doyle, Anoop Enjeti, Michael Kelso, Daniel Tillett |
Scheme | MRFF - Cardiovascular Health Mission - Cardiovascular Health |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2025 |
GNo | G2200136 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
A dual approach to activate a tumour suppressor for breast cancer therapy$605,670
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Associate Professor Jonathan Morris |
Scheme | Ideas Grants |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2024 |
GNo | G2100530 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
20212 grants / $218,625
Cracking the Code: The launch of a genomic, epigenetic and proteomic pre-clinical platform to improve the treatment of paediatric leukemias$122,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills, Doctor Heather Lee, Doctor Janis Chamberlain, Doctor Frank Alvaro, Doctor Anoop Enjeti, Associate Professor Kathryn Skelding, Doctor Lisa Lincz, Doctor Abdul Mannan, Doctor Heather Murray, Kristy McCarthy, Elizabeth Heskett, Paola Baeza, Kathleen Irish |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2001337 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
HMRI Transition Funding - HCRA$96,625
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Rodney Scott, Professor Christine Paul, Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2022 |
GNo | G2100975 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20202 grants / $775,618
Targeting DNA-PK in acute myeloid leukaemia$761,618
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Anoop Enjeti |
Scheme | Ideas Grants |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | G1900595 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
Eppendorf epMotion 96 bench top liquid handling robot$14,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Partner Funding |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2100822 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20193 grants / $162,681
Single cell transcriptomic analysis of lung cancer$100,000
Funding body: Maitland Cancer Appeal Committee Incorporated
Funding body | Maitland Cancer Appeal Committee Incorporated |
---|---|
Project Team | Associate Professor Nikki Verrills, Professor Philip Hansbro, Conjoint Professor Peter Wark, Conjoint Associate Professor Christopher Grainge |
Scheme | Research Funding |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2020 |
GNo | G1901278 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
An integrated proteomics approach to identify novel targets for treatment of Acute Myeloid Leukaemia$58,181
Funding body: Takeda Pharmaceutical Company Limited
Funding body | Takeda Pharmaceutical Company Limited |
---|---|
Project Team | Associate Professor Nikki Verrills, Professor Matt Dun, Professor Richard D’Andrea, Dr David Ross |
Scheme | COCKPI-T Australia |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1801222 |
Type Of Funding | C3400 – International For Profit |
Category | 3400 |
UON | Y |
Kyratec PCR machine$4,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Professor Matt Dun |
Scheme | Early and Mid-Career Equipment Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900111 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20186 grants / $875,586
Hunter Cancer Biobank$725,684
Funding body: NSW Health Pathology - Pathology North
Funding body | NSW Health Pathology - Pathology North |
---|---|
Project Team | Professor Marjorie Walker, Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Professor Pradeep Tanwar, Associate Professor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Professor Nikola Bowden, Associate Professor Kelly Kiejda, Professor Simon Keely, Doctor Christopher Rowe |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2022 |
GNo | G1800704 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Capillary Flow Two Dimensional High Pressure Liquid Chromatography (HPLC) system$75,761
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Brett Nixon, Professor Matt Dun, Associate Professor Nikki Verrills, Professor Hubert Hondermarck, Associate Professor Mark Baker, Doctor Elizabeth Bromfield |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800470 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
Targeting Reactive Oxygen Species Generation as a Novel Treatment Target in Acute Myeloid Leukaemia - RA support$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Doctor Jonathan Sillar, Doctor Anoop Enjeti, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800399 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
A new approach for treating therapy resistant breast cancer$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Severine Roselli Dayas, Associate Professor Nikki Verrills, Doctor Nick Zdenkowski, Dr James Lynam |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801453 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Targeting DNA repair for the improved treatment of blood cancers$20,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800611 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Jennie Thomas Medical Research Travel Grant - Nikita Panicker$4,141
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Miss Nikita Panicker, Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Professor Matt Dun |
Scheme | Jennie Thomas Medical Research Travel Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800024 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20175 grants / $1,082,215
Novel models to advance our understanding of mammalian development$974,590
Funding body: ARC (Australian Research Council)
Funding body | ARC (Australian Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills, Ms Melody Coutman |
Scheme | Future Fellowships |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2021 |
GNo | G1601252 |
Type Of Funding | C1200 - Aust Competitive - ARC |
Category | 1200 |
UON | Y |
Novel models to advance our understanding of mammalian development$31,125
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Future Fellowship Support |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2020 |
GNo | G1701290 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS$27,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1700272 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Determining the mechanisms underpinning leukaemic transformation for children suffering from Shwachman-Diamond Syndrome (SDS)$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills, Doctor Bryony Ross, Doctor Anoop Enjeti, Dr Jeremy Robertson |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1701574 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Targeting a tumour suppressor for new cancer therapies $24,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Professor Matt Dun, Doctor Severine Roselli Dayas |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | G1700588 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20161 grants / $100,000
Targeting DNA repair for the improved treatment of blood cancers$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | G1601127 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20157 grants / $1,326,627
High resolution fourier transform mass spectrometry platform for the discovery of novel cancer biomarkers and drug targets using label-free and isobaric-tagged approaches for quantitative proteomics.$500,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Xu Dong Zhang, Professor Matt Dun, Professor Jennifer Martin, Professor Hubert Hondermarck, Distinguished Emeritus Professor John Aitken, Associate Professor Nikki Verrills, Professor Pradeep Tanwar, Professor Rodney Scott, Professor Maria Kavallaris, Dr Darren Saunders |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | G1500599 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
A novel biomarker for luminal B breast cancer$359,577
Funding body: Cancer Council NSW
Funding body | Cancer Council NSW |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2017 |
GNo | G1400487 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
High resolution fourier transform mass spectrometry platform for the discovery of novel cancer biomarkers and drug targets using label-free and isobaric-tagged approaches for quantitative proteomics.$196,250
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Xu Dong Zhang, Professor Matt Dun, Professor Jennifer Martin, Professor Hubert Hondermarck, Distinguished Emeritus Professor John Aitken, Associate Professor Nikki Verrills, Professor Pradeep Tanwar, Professor Rodney Scott, Professor Maria Kavallaris, Dr Darren Saunders |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500935 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Investigating the in-vitro efficacy of potential anti-CFIDS compounds in c-kit+ myeloid cells$195,800
Funding body: National CFIDS Foundation Inc.
Funding body | National CFIDS Foundation Inc. |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1401533 |
Type Of Funding | International - Non Competitive |
Category | 3IFB |
UON | Y |
Identification of better diagnostic tools and new treatment options for children suffering from Shwachman-Diamond Syndrome (SDS)$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500757 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
A novel approach to cancer therapy - targeting patients with loss of a specific tumour suppressor gene$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1501201 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Mengna Chi, Associate Professor Nikki Verrills, Doctor Roger Liang |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600224 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
20148 grants / $997,013
Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$600,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills, Associate Professor Martin Larsen |
Scheme | Early Career Fellowship |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2016 |
GNo | G1300952 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Targeting a tumour in breast cancer$162,800
Funding body: Pink Frangipani Ball Organising Committee
Funding body | Pink Frangipani Ball Organising Committee |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Research Project |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2020 |
GNo | G1400881 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
JuLI Stage $71,674
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Pradeep Tanwar, Professor Eileen McLaughlin, Emeritus Professor Robin Callister, Professor Xu Dong Zhang, Professor Murray Cairns, Professor Brett Nixon, Professor Hubert Hondermarck, Associate Professor Phillip Dickson, Associate Professor Nikki Verrills, Professor Matt Dun, Doctor Jessie Sutherland, Doctor Janani Kumar, Professor Jay Horvat, Associate Professor Susan Hua, Prof LIZ Milward, Associate Professor Estelle Sontag, Professor Dirk Van Helden, Doctor Janet Bristow, Doctor Jean-Marie Sontag |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1500860 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$67,539
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2017 |
GNo | G1301353 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Myr-C310: A new treatment for childhood leukaemia$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301349 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Preclinical testing of a novel therapeutic strategy for breast cancer $25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301439 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML).$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301442 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills |
Scheme | Near Miss Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301404 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20134 grants / $414,849
Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,253
Funding body: Cancer Council NSW
Funding body | Cancer Council NSW |
---|---|
Project Team | Professor Xu Dong Zhang, Associate Professor Nikki Verrills, Doctor Chen Chen Jiang |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2016 |
GNo | G1200388 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1301348 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Ultra-Low Temperature Cryogenic Freezer$24,596
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Jude Weidenhofer, Doctor Rick Thorne, Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills, Professor Pradeep Tanwar, Associate Professor Phillip Dickson, Professor Murray Cairns, Professor Hubert Hondermarck, Professor Xu Dong Zhang, Associate Professor Estelle Sontag, Doctor Chen Chen Jiang, Prof LIZ Milward, Doctor Jean-Marie Sontag, Associate Professor Paul Tooney, Doctor Severine Roselli Dayas, Professor Matt Dun, Professor Chris Dayas, Doctor Lin Kooi Ong, Professor Dirk Van Helden, Mr Ben Copeland, Doctor Gabrielle Briggs, Emeritus Professor Leonie Ashman, Emeritus Professor John Rostas |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1201189 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
Proteomics of Cancer$6,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills, Associate Professor Anoop Enjeti |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1300054 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
20128 grants / $747,800
The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$292,300
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Emeritus Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Conjoint Associate Professor Barbara Young, Professor Hubert Hondermarck, Emeritus Professor Leonie Ashman, Professor Xu Dong Zhang, Associate Professor Kelly Kiejda, Associate Professor Nikki Verrills, Doctor Jennette Sakoff, Ms Janine Lombard, Doctor Jude Weidenhofer, Professor Pradeep Tanwar |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2012 |
Funding Finish | 2015 |
GNo | G1200798 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Activating a tumour suppressor for leukaemia therapy$260,000
Funding body: Cancer Council NSW
Funding body | Cancer Council NSW |
---|---|
Project Team | Associate Professor Nikki Verrills, Dr Anthony Don, Associate Professor Anoop Enjeti, Associate Professor Jonathan Morris |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2014 |
GNo | G1100512 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Activating a tumour suppressor for leukaemia therapy they receive$100,000
Funding body: Cure Cancer Australia Foundation
Funding body | Cure Cancer Australia Foundation |
---|---|
Project Team | Associate Professor Nikki Verrills, Dr Anthony Don, Associate Professor Anoop Enjeti, Associate Professor Jonathan Morris |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1200007 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Murray Cairns, Associate Professor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1100983 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
Role of CaMKII targeting in neuronal susceptibility to excitotoxic cell death$20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Emeritus Professor John Rostas, Professor Neil Spratt, Associate Professor Phillip Dickson, Associate Professor Nikki Verrills |
Scheme | Near Miss Grant |
Role | Investigator |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1200673 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Activating a tumour suppressor for leukaemia therapy$20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Near Miss Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1200678 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones |
Scheme | Near Miss Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1200679 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
FASEB Protein Phosphatases, Snowmass, Colorado USA, 15 - 20 July 2012$1,500
Funding body: University of Newcastle - Faculty of Health and Medicine
Funding body | University of Newcastle - Faculty of Health and Medicine |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2013 |
GNo | G1200803 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20118 grants / $2,325,820
Molecular characterisation of TRAIL-regulated signal transduction pathways and their role in the development, persistence, and exacerbation of allergic airways disease$615,048
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Joerg Mattes, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2013 |
GNo | G1000314 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
Targeting a tumour suppressor, PP2AS for new Leukaemia therapies$600,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Early Career Fellowship |
Role | Lead |
Funding Start | 2011 |
Funding Finish | 2016 |
GNo | G1000861 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Priority Research Centre for Cancer$555,811
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Emeritus Professor John Forbes, Emeritus Professor Leonie Ashman, Professor Nikola Bowden, Professor Gordon Burns, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Professor Peter Stanwell, Doctor Rick Thorne, Associate Professor Nikki Verrills |
Scheme | Priority Research Centre |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2016 |
GNo | G1101013 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Chemical Biology$444,961
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Adam McCluskey, Doctor Warwick Belcher, Associate Professor Ian Grainge, Professor Christopher Grof, Cprof PETER Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Emeritus Professor Ray Rose, Doctor Jennette Sakoff, Associate Professor Nikki Verrills |
Scheme | Priority Research Centre |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2013 |
GNo | G1100052 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Preclinical testing of PP2A activating compounds for the treatment of childhood acute lymphoblastic leukaemia$40,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Dr Anthony Don |
Scheme | Paediatric Oncology Project Grant |
Role | Lead |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1001001 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills, Emeritus Professor John Rostas |
Scheme | Breast Cancer Project Grant |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1001005 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Targeting PP2A as a Novel Therapeutic Strategy for mutant FLT3* Acute Myeloid Leukaemia$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Doctor Kyu-Tae Kim, Associate Professor Anoop Enjeti |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1000990 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
IMPLEN NanoPhotometer pearl$10,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Prof ULLI Schall, Associate Professor Phillip Dickson, Professor Rohan Walker, Doctor Rick Thorne, Professor Chris Dayas, Associate Professor Nikki Verrills, Doctor Janet Bristow, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Doctor Jude Weidenhofer, Prof LIZ Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Doctor Dan Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1100030 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20104 grants / $839,000
An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$500,000
Funding body: ARC (Australian Research Council)
Funding body | ARC (Australian Research Council) |
---|---|
Project Team | Professor Adam McCluskey, Distinguished Emeritus Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Emeritus Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Conjoint Professor Rob Atkin, Associate Professor Clovia Holdsworth, Associate Professor Mark Baker, Associate Professor Nikki Verrills, Professor Gottfried Otting, Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher |
Scheme | Linkage Infrastructure Equipment & Facilities (LIEF) |
Role | Investigator |
Funding Start | 2010 |
Funding Finish | 2010 |
GNo | G0190402 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$280,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Adam McCluskey, Distinguished Emeritus Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Emeritus Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Conjoint Professor Rob Atkin, Associate Professor Clovia Holdsworth, Associate Professor Mark Baker, Associate Professor Nikki Verrills, Professor Gottfried Otting, Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2010 |
Funding Finish | 2010 |
GNo | G1000873 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
ABI 7500 Real Time PCR System $34,000
Funding body: NHMRC (National Health & Medical Research Council)
Epigenetic methylation of PP2A subunit promoters in breast cancer$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Doctor Martin Horan |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2010 |
Funding Finish | 2010 |
GNo | G0900148 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
20094 grants / $1,161,000
An Advanced Mass Spectrometry Facility for Applications in Proteomics and Organic Chemistry$495,000
Funding body: ARC (Australian Research Council)
Tetraspanin proteins in prostate cancer progression and prognosis$341,000
Funding body: Cancer Council NSW
Funding body | Cancer Council NSW |
---|---|
Project Team | Emeritus Professor Leonie Ashman, Associate Professor Nikki Verrills, Conjoint Professor Jim Denham |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2009 |
Funding Finish | 2011 |
GNo | G0188877 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Confocal Laser Scanning Microscopy for Live Cell Imaging$275,000
Funding body: ARC (Australian Research Council)
Funding body | ARC (Australian Research Council) |
---|---|
Project Team | Conjoint Professor Keith Jones, Professor Eileen McLaughlin, Distinguished Emeritus Professor John Aitken, Emeritus Professor Ray Rose, Emeritus Professor John Patrick, Conjoint Professor Christina Offler, Aprof DAVID McCurdy, Emeritus Professor Leonie Ashman, Professor Gordon Burns, Professor Dirk Van Helden, Associate Professor Nikki Verrills, Professor Brett Nixon, Doctor Shaun Roman, Professor Yong-Ling Ruan, Doctor Rick Thorne, Prof MIKE Calford |
Scheme | Linkage Infrastructure Equipment & Facilities (LIEF) |
Role | Investigator |
Funding Start | 2009 |
Funding Finish | 2009 |
GNo | G0189038 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
An Advanced Mass Spectrometry Facility for Applications in Proteomics and Organic Chemistry$50,000
Funding body: ARC (Australian Research Council)
20085 grants / $1,646,290
HMRI Cancer Research Program - MRSP Infrastructure$1,031,290
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Emeritus Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Associate Professor Nikki Verrills |
Scheme | NSW MRSP Infrastructure Grant |
Role | Investigator |
Funding Start | 2008 |
Funding Finish | 2009 |
GNo | G0188622 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
PP2A: a novel target for leukaemia therapy$300,000
Funding body: Cancer Council NSW
Funding body | Cancer Council NSW |
---|---|
Project Team | Associate Professor Nikki Verrills, Emeritus Professor Leonie Ashman, Professor Alistair Sim, Associate Professor Danilo Perrotti, Assoc. Prof Timothy Hughes, Dr David Thomas |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2010 |
GNo | G0187694 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Functional investigations of novel SET splice isoforms in acute myeloid leukaemia and their potential as a therapeutic target.$270,000
Funding body: Anthony Rothe Memorial Trust
Funding body | Anthony Rothe Memorial Trust |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2010 |
GNo | G0188185 |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | Y |
Novel Alternative Splice Isoforms of the SET Oncogene in Acute Myeloid Leukaemia $25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | G0188462 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
PP2A: A new target for asthma therapy$20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Alistair Sim, Associate Professor Nikki Verrills, Professor John Scott, Conjoint Professor Peter Wark |
Scheme | Near Miss Grant |
Role | Investigator |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | G0188395 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20077 grants / $528,630
FACSAria - Fluorescence activated cell sorter$300,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Associate Professor Nikki Verrills, Emeritus Professor Leonie Ashman, Distinguished Emeritus Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff |
Scheme | Research Infrastructure Grants |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0187666 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
The role of protein phosphatase 2A in breast cancer$75,000
Funding body: Cure Cancer Australia Foundation
Funding body | Cure Cancer Australia Foundation |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0186797 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Emeritus Professor Leonie Ashman, Distinguished Emeritus Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff |
Scheme | Equipment Grant |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0188207 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Differential regulation of human mast cell degranulation by discrete forms of protein phosphatase 2A$50,000
Funding body: Asthma Foundation of New South Wales
Funding body | Asthma Foundation of New South Wales |
---|---|
Project Team | Professor Alistair Sim, Associate Professor Nikki Verrills, Professor Paul Foster, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Dr Gregory Kranias |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0187247 |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | Y |
The tumour suppressor gene, PP2A, in breast cancer and its potential as a new target for therapy$29,930
Funding body: Ramaciotti Foundations
Funding body | Ramaciotti Foundations |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0188055 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Polymerase Chain Reaction (PCR) machine and Spectrophotometer$20,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Emeritus Professor Leonie Ashman, Professor Alistair Sim, Associate Professor Nikki Verrills |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0188195 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
American Association of Cancer Research, LA Convention Centre, Los Angeles, USA, 14/4/2007 - 18/4/2007$1,700
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0187550 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20066 grants / $505,157
The role of protein phosphates in regulating the cytoskeletal dynamics of cancer cells$292,062
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Training (Postdoctoral) Fellowships - Peter Doherty Biomedical Fellowship (Australia) |
Role | Lead |
Funding Start | 2006 |
Funding Finish | 2010 |
GNo | G0185634 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
Live cell imaging facility$149,100
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Doctor Rick Thorne, Associate Professor Nikki Verrills, Professor Alistair Sim, Professor Gordon Burns |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2006 |
Funding Finish | 2006 |
GNo | G0186146 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Investigating the functional role of altered expression and point mutations in the tumour suppressor gene PP2A$50,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Special Competitive Research Fund for Early Career Researchers in Cancer |
Role | Lead |
Funding Start | 2006 |
Funding Finish | 2007 |
GNo | G0186082 |
Type Of Funding | Not Known |
Category | UNKN |
UON | Y |
Novel protein phosphatase interactions in cancer$10,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Professor Alistair Sim |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2006 |
Funding Finish | 2006 |
GNo | G0186480 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
High speed computer for a live cell imaging system$3,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Rick Thorne, Professor Gordon Burns, Associate Professor Nikki Verrills, Professor Alistair Sim |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2006 |
Funding Finish | 2006 |
GNo | G0187279 |
Type Of Funding | Not Known |
Category | UNKN |
UON | Y |
BioRad Mini-PROTEAN3 Electrophoresis system$995
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Emeritus Professor Leonie Ashman, Associate Professor Phillip Dickson, Emeritus Professor Peter Dunkley, Emeritus Professor John Rostas, Conjoint Professor Judith Scott, Professor Alistair Sim, Associate Professor Nikki Verrills |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2006 |
Funding Finish | 2006 |
GNo | G0187280 |
Type Of Funding | Not Known |
Category | UNKN |
UON | Y |
20051 grants / $2,430
Europhosphatases Conference 2005, 10-14 July 2005$2,430
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2005 |
Funding Finish | 2005 |
GNo | G0185546 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20041 grants / $2,400
12th International Conference on Second Messenger and Phosphoproteins, 3-7 August 2004$2,400
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2004 |
Funding Finish | 2004 |
GNo | G0184543 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2023 | PhD | Understanding How Aging Impacts The Proteome To Make The Brain Susceptible To Developing Alzheimer’s Disease. | PhD (Anatomy), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2022 | PhD | Activation Of A Tumour Suppressor In Triple Negative Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2019 | PhD | Epigenetic Heterogeneity in Haematological Malignancies | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2018 | PhD | Investigation into the Anti-Acute Myeloid Leukaemia and Complementary Health Benefits of Medicinal Cannabis | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2017 | PhD | Molecular Characterisation of Treatment Resistance in Acute Myeloid Leukaemia. | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2016 | PhD | Reactive Oxygen Species Promoted Leukaemogenesis; Altered Signalling Pathways as New Drug Targets for the Improved Treatment of Acute Myeloid Leukaemia | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2007 | PhD | The role of protein phosphatases in breast cancer | Biochemistry & Cell Biology, University of Newcastle | Co-Supervisor |
2006 | PhD | Role of PP2A in cancer | Biochemistry & Cell Biology, University of Newcastle | Co-Supervisor |
2006 | PhD | PP2A in mast cell function | Biochemistry & Cell Biology, University of Newcastle | Co-Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2024 | PhD | Multiomic Characterisation of Cellular Signalling Regulated by PP2A-B55a in Breast Cancer and Development | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2022 | PhD | Smart Drug Delivery System Based on Core-Shell Silica Nanomaterials for Prostate Cancer | PhD (Materials Science & Eng), College of Engineering, Science and Environment, The University of Newcastle | Co-Supervisor |
2022 | PhD | Multifunctional Core-Shell Mesoporous Silica Nanoparticles for Lung Cancer Therapy | PhD (Materials Science & Eng), College of Engineering, Science and Environment, The University of Newcastle | Co-Supervisor |
2022 | PhD | Mesoporous Silica Nanoparticles with 3D Porous Structures for Biomedical Applications | PhD (Materials Science & Eng), College of Engineering, Science and Environment, The University of Newcastle | Co-Supervisor |
2022 | PhD | Targeting Reactive Oxygen Species for the Treatment of Acute Myeloid Leukaemia | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2022 | PhD | Functional Role of Protein Phosphatase 2A and its Regulatory Subunit B55a in Development and Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2022 | PhD | Molecular and Phosphoproteomic Characterisation of FLT3 Inhibitor Resistance in Acute Myeloid Leukaemia | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2021 | PhD | The Molecular and Cellular Analysis of Cell Lines Derived from Patients with Schizophrenia | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2020 | PhD | Identifying Novel Therapeutic Targets for the Treatment of Acute Myeloid Leukaemia | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2019 | PhD | The Renin-Angiotensin System in Endometrial Cancer | PhD (Human Physiology), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2019 | PhD | The Functional Role of PPP2R2A in Luminal Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2016 | PhD | Enhancing the Power of Endogenous Protein Phosphatase 2A to Combat Asthmatic Inflammation: Role for MAPKs an Tristetraprolin | Pharmacy, The University of Sydney | Co-Supervisor |
2016 | PhD | The impact of precise MKP-1 regulation and modulation on cytokine expression in asthma and airways remodelling | Pharmacy, The University of Sydney | Co-Supervisor |
2014 | PhD | Targeting PP2A Activation as a Novel Therapeutic Strategy for Receptor Tyrosine Kinase Driven Leukemia | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2012 | PhD | The Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2011 | PhD | Regulation of Mast Cell Degranulation by Protein Phosphatase 2A | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2010 | PhD | Regulation of the Tumour Suppressor PP2A by Oncogenic Tyrosine Kinases | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
Research Projects
Verrills Laboratory 2012 -
Grants
A dual approach to activate a tumour suppressor for breast cancer therapy
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Severine Roselli Dayas, Associate Professor Jonathan Morris, Associate Professor Nikki Verrills |
Scheme | Ideas Grants |
Targeting DNA-PK in acute myeloid leukaemia
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Anoop Enjeti |
Scheme | Ideas Grants |
Publications
Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7 47465-47478 (2016) [C1]
Murray HC, Dun MD, Verrills NM, 'Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer', Expert Opinion on Drug Discovery, 12 431-447 (2017) [C1]
Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al., 'Functional importance of PP2A regulatory subunit loss in breast cancer', Breast Cancer Research and Treatment, 166 117-131 (2017) [C1]
Dun MD, Mannan A, Rigby CJ, Butler S, Toop HD, Beck D, et al., 'Shwachman Bodian Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia', Leukemia, 34 3393-3397 (2020) [C1]
Panicker N, Coutman M, Lawlor-O'Neill C, Kahl RGS, Roselli S, Verrills NM, 'Ppp2r2aKnockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55 alpha, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development', FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 8 (2020) [C1]
Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, et al., 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', LEUKEMIA, 35 1782-1787 (2021)
Students
Program | Research Title |
---|---|
PhD College of Health, Medicine and Wellbeing |
Multiomic Characterisation of Cellular Signalling Regulated by PP2A-B55a in Breast Cancer and Development |
Collaborators
Name | Organisation |
---|---|
Doctor Heather Constance Murray | University of Newcastle |
Doctor Nikita Panicker | University of Newcastle |
Miss Charley Louise Lawlor-O'Neill | University of Newcastle |
Doctor Lauren Frances Watt | University of Newcastle |
Miss Kasey Erin Miller | University of Newcastle |
Mr Joshua Stephen Sidney Brzozowski | University of Newcastle |
Miss Yanfang Chen | University of Newcastle |
Doctor Severine Roselli Melanie Dayas | University of Newcastle |
Edit
News
News • 8 Nov 2021
$4.5m in NHMRC Ideas Grants supports quest to improve human health
University of Newcastle researchers will explore new stroke prevention therapies, preterm birth interventions and a dual approach to breast cancer treatment with the support of $4.5m in National Health and Medical Research Council (NHMRC) Ideas grants.
News • 2 Nov 2020
New treatment idea discovered for leukaemia
Newcastle researchers have discovered a new way to kill leukaemia cells.
News • 18 Dec 2019
NHMRC awards $9.3 million to 13 University of Newcastle projects
The University of Newcastle has received more than $9.3 million in funding to support projects aiming to solve some of the world’s most critical health problems and improve the lives of millions of Australians.
News • 26 Jun 2018
Pink Frangipani Ball blossoms hope for breast cancer patients
Current chemotherapy and radiation treatment options for breast cancer patients are grueling, and not all patients see positive results, however with funding raised from the 2018 Pink Frangipani Ball, Dr Nikki Verrills and her research team hope to develop revolutionary new therapies.
News • 5 Jun 2017
UON researchers awarded $4.5m in ARC fellowships
Three University of Newcastle (UON) researchers have today been awarded more than $4.5m in prestigious Australian Research Council (ARC) fellowships.
News • 1 May 2015
$1m for visionary cancer researchers
Two of the University of Newcastle's leading researchers have been awarded more than $1m in grants to focus on discovering new methods of curbing and treating cancer.
News • 12 Jan 2015
$1 million in Cancer Council NSW project grants
Two University of Newcastle (UON) cancer researchers from the School of Biomedical Sciences and Pharmacy in the Faculty of Health and Medicine have been awarded more than $1 million in Cancer Council NSW project grants for 2015.
Associate Professor Nikki Verrills
Position
Associate Professor
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Focus area
Medical Biochemistry
Contact Details
nikki.verrills@newcastle.edu.au | |
Phone | (02) 4921 5619 |
Fax | (02) 4921 6903 |
Links |
YouTube YouTube YouTube |
Office
Room | LS3-46 |
---|---|
Building | Life Sciences |
Location | Callaghan University Drive Callaghan, NSW 2308 Australia |